The part that shouldn't have worked, and everyone who mattered said so. In 1974, cancer researcher Judah Folkman hired Robert Langer, who'd just finished a chemical engineering PhD at MIT, to solve a specific problem: find a way to release large biological molecules from a polymer implant slowly and steadily, instead of all at once. Folkman asked around, including Paul Flory, a Nobel laureate in chemistry for his work on polymers -- and was told it wasn't possible. Langer spent two years testing methods that failed. In 1976, he finally found one that worked, publishing it in Nature: a way to release molecules as large as 2,000,000 daltons from a biocompatible polymer, continuously, for over 100 days. The field of controlled-release drug delivery is generally dated to this one paper.
The same lab kept going, for decades, into a specific technology: the lipid nanoparticle. Langer began conceptualizing lipid-based carriers for delivering fragile molecules into cells starting in that same era. Over the following decades his lab became one of the most prolific sources of licensed biomedical technology anywhere -- more than 1,500 patents, licensed or sublicensed to over 400 pharmaceutical, chemical, biotech, and medical device companies, and more than 40 companies co-founded directly out of the work. Lipid nanoparticles specifically solved a problem that had stalled an entire class of medicine for years: mRNA is fragile and gets destroyed almost instantly in the body on its own. A lipid nanoparticle is what protects it long enough to reach a cell and be used.
2010: the lab work becomes a company built specifically around that problem. Langer co-founded Moderna with Derrick Rossi, Kenneth Chien, and Noubar Afeyan, explicitly to build a platform combining mRNA chemistry with lipid nanoparticle delivery at manufacturing scale -- not a side project, the company's entire founding thesis.
December 18, 2020: the platform becomes mRNA-1273. The FDA issued Emergency Use Authorization for Moderna's COVID-19 vaccine -- a lipid-nanoparticle-encapsulated, mRNA vaccine encoding the SARS-CoV-2 spike protein. The specific lipid formulation (SM-102, DSPC, cholesterol, PEG2000-DMG) is a direct technical descendant of the delivery problem Langer's lab had been solving since the 1970s. Worth being precise rather than implying one lab ended the pandemic alone: Pfizer-BioNTech's vaccine, authorized days earlier, also used lipid nanoparticle delivery but through a separate, independent lineage of LNP research (Acuitas Therapeutics, tracing to different Vancouver-based work), not Langer's lab. Two real, separate technical lines converged on the same solution around the same time -- Langer's is one direct, traceable arc, not the only one.
Where this arc actually lands: on a chart already published on this site. The Fed Funds Rate page shows initial unemployment claims spiking from roughly 210,000 to a peak of 6,137,000 in three weeks in March-April 2020 -- the single largest, fastest move in that entire series. The Employment Trend shows the resulting collapse and the recovery that followed it. The mRNA vaccines, Moderna's among them, are real, documented contributors to why that recovery was able to happen when it did -- not the only factor (fiscal stimulus and the natural course of the pandemic itself both mattered too), but a genuine, traceable one. A result from a rejected 1976 experiment is sitting inside the steepest line this site has ever charted.